Greg’s extensive scientific background gives him a valuable understanding of technical issues that can underlie IP matters, particularly in the life sciences field. He has advised and represented clients on small molecule pharmaceuticals, biologics (originators and biosimilars), medical devices (hardware and software), as well as in the cosmetics, chemicals, technology, shipping and online publishing sectors.
Greg has represented clients in many cases before both the English High Court (including Patents Court) and Court of Appeal. In addition, Greg has extensive experience of strategic multinational litigation in multiple jurisdictions, including at the EPO, through global pharmaceutical product coordination projects for many clients.
He has also spent time on secondment to the IP litigation department of a leading IP law firm in the Netherlands as well as the UK legal department of a global healthcare IT company, working on non-contentious IP/IT, regulatory and commercial matters.
Greg is a regular contributor to the monthly EPO reports which Bristows produce for the CIPA Journal and writes on UK cases for a number of IP blogs. He is also the editor of our On the Pulse life sciences microsite and one of the editors of our Biotech Review publication which explores key issues and developments in the biotech space, and co-authored the UK chapter of the AIPLA’s International Patent Litigation guide.
- Novartis v Focus, Actavis & Teva – Patents Court and Court of Appeal patent litigation concerning transdermal dosage regime patent for rivastigmine (Exelon®), including global coordination of parallel litigation and EPO opposition.
- Parainen Pearl Shipping v Kristian Gerhard Jebsen Skipsrederi – case on exhaustion of patent rights in a pneumatic cement discharge system for a ship, including a pan-European jurisdiction challenge.
- Orion v SS for Health and Social Care & Ever Neuro – judicial review challenge to decision of MHRA to grant generic marketing authorisation for dexmedetomidine hydrochloride, involving question of whether pre-accession Czech MA was compatible with Directive 2001/83/EC and thus the first MA for the purposes of calculating the term of data exclusivity.
- Celltrion v Biogen, Roche & Genentech – clearing the way revocation action in the Patents Court in relation to biosimilar rituximab product (MabThera®).
- Merck Serono v AbbVie – clearing the way revocation action in the Patents Court in relation to biosimilar adalimumab product (Humira®).
- ConvaTec v Smith & Nephew – long-running case in the Patents Court and Court of Appeal concerning patents and claims to misuse of confidential information in relation to gel-forming wound dressings (Durafiber®), and subsequent damages claim under a cross-undertaking.
- Allergan v Ipsen – patent litigation in the Patents Court on second medical use patents to botulinum toxin (Dysport®).
- Servier v National Institute of Health and Clinical Excellence (NICE) – successful judicial review of NICE decision not to recommend a client’s osteoporosis treatment (Protelos®).
- BA (Hons) Natural Sciences (Neuroscience), University of Cambridge
- DPhil Neuroscience, University of Oxford
- Diploma in Intellectual Property Law and Practice, University of Oxford
- Qualified 2007
- Partner 2017
What others say
“An excellent strategist; very relaxed and pleasant to work with.”Juve UK 2022
“Great patent litigator who is confident with the technical side of a case, but also has a good tactical legal brain.”IAM Patent 1000 2021
Gregory is "a creative thinker – he can propose innovative options as solutions."Legal 500 2020
Gregory Bacon "is particularly talented" in his area.Legal 500 2020